Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine
Consumer Health Gets Little Mention In Q1 Results After Sales Dip 7%
Executive Summary
Along with its Q1 results including a 7.3% drop in consumer health sales to €1.11bn ($1.35bn), Sanofi announces 10-mg famotidine tablets branded Zantac 360° will be available in the US in June.
You may also be interested in...
Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules
Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.
When Strike Three Was Called In Federal Court, Ranitidine Complaint Limited To Zantac Brand Firms
Rulings on first two MDL complaints dismissed all claims against distributors, retailers and generic manufacturers and allegations of Racketeer Influenced and Corrupt Organization Act against brand-name ranitidine manufacturers.
First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride
Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.